Navigation Links
Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
Date:8/12/2008

Medarex to Receive Milestone Payment from MedImmune

PRINCETON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that its partner MedImmune, Inc. has initiated a Phase 2A multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus (SLE or lupus). MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System(R). Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount.

The Phase 2A clinical trial is designed to evaluate the safety and tolerability of multiple subcutaneous dose schedules of MEDI-545 or placebo in adult patients with moderate to severe active lupus. The study will also assess the effects of MEDI-545 on disease activity in lupus patients. This randomized, double-blind, placebo-controlled trial is expected to enroll 80 patients and will be conducted at 20 sites in the United States.

MedImmune is also conducting a Phase 1 clinical trial for MEDI-545 in idiopathic inflammatory myositis, an immunological disease that involves chronic muscle inflammation, pain and weakness.

"Data from an earlier reported placebo-controlled Phase 1 study suggested therapeutic activity with single doses in patients with lupus and demonstrated an acceptable safety profile," said Geoffrey M. Nichol, M.B.Ch.B., Senior Vice President of Product Development at Medarex. "We are very excited about the role of the interferon alpha inflammatory pathway and look forward to exploring its potential in treating patients with lupus and other autoimmune diseases."

About MEDI-545

MEDI-545 (previously known as MDX-1103) is a fully human monoclonal antibody targeting
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... -- Bronstein, Gewirtz & Grossman, LLC is investigating potential ... Celladon Corporation ("Celladon" or the "Company") (NasdaqGM: CLDN -News).  ... or his investor relations coordinator Eitan Kimelman ... The investigation concerns whether Celladon and certain of its ... of the Securities Exchange Act of 1934.  ...
(Date:4/27/2015)... , April 27, 2015 Kalorama Information ... medical records (EMR) to grow well past the ... providers, according to a recent report.  The healthcare ... sales and continued efficiency improvements will grow the ... the next five years.  The market for EMR ...
(Date:4/27/2015)... BRH Medical, Ltd., today announced that it ... (510k) with the US Food and Drug Administration (FDA) ... feedback from the FDA during the next quarter and ... pre-market clearance. Additional pre-market regulatory filings are anticipated during ... BRH Medical, commented, "We are thrilled to have reached ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Kalorama: EMR Market Expected To Grow Beyond Incentives 2Kalorama: EMR Market Expected To Grow Beyond Incentives 3BRH Medical, Ltd., Announces Filing of a Pre-Market Submission with the US Food and Drug Administration (FDA) for the BRH-A2 Tissue Management System 2
... WASHINGTON, Nov. 2 The owner and operator of ... guilty to defrauding the Medicare program, announced Assistant Attorney ... Attorney Tim Johnson of the Southern District of Texas ... of Health & Human Services (HHS). , Noel Wayne ...
... , BOSTON, Nov. 2 Schering-Plough Corporation (NYSE: ... ongoing Phase IIa study of narlaprevir (SCH 900518), its ... treatment-naive patients with chronic hepatitis C virus (HCV) genotype ... in which patients received a 4-week lead-in of PEGINTRON(R) ...
Cached Medicine Technology:Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 2Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 3Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 4Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 5Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 6Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 7Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C 8
(Date:4/27/2015)... (PRWEB) April 27, 2015 Array ... exchange technology, has announced that Lance Hood, senior director ... the fourth annual Direct-to-Consumer Health Care Marketing Summit ... by David Smith, Partner and Director of Payer Services, ... health care consumerism – through a retail/e-commerce perspective – ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Beckman Coulter ... Next-Gen sequencing to study the evolution of neural circuitry ... which will review the mechanisms by which analogous forms ... (LR) body flexions, evolved independently in certain sea slug ... be broadcast live April 30, 2015 at 8:00am PT. ...
(Date:4/27/2015)... The Doctors on Liens mission ... personal injury attorneys with the best doctors working on a ... growth throughout their history and that trend continues with the ... his team in the Tujunga / Sunland area. ... therapist, patients can find comprehensive care and detailed documentation of ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
(Date:4/27/2015)... OH (PRWEB) April 27, 2015 Douglas ... to help his clients feel secure, but also helps secure ... to 7 p.m., Douglas will be manning a booth at ... Center, Lausche Building, 717 E. 17th Ave., Columbus, Ohio. ... worthy event that will feature hundreds of adoptable pets from ...
Breaking Medicine News(10 mins):Health News:Array Health’s Senior Director of Marketing to Present at The Fourth Annual Direct-to-Consumer Health Care Marketing Summit 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Prominent Doctors with Distinguished Backgrounds Join Doctors on Liens in Tujunga 2Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2Health News:Farmers Insurance Agent Douglas Fitzpatrick Ensures Pets Find Homes 2
... of these infant medicines, not product safety, is ... the voluntary withdrawal,- This withdrawal does not affect cough and cold medicines for children ... ... for infants and,children will occur at the October 18 and 19 FDA advisory committee ...
... Oct. 11 Businesses can no longer afford ... spend more than,75 billion dollars on obesity-attributable health ... are lost to obesity-related illness each,year(2). Other costs ... and high turnover rates. Today, business leaders, ...
... * concentrated Tylenol(R) Infants, Drops Plus Cold and ... * PediaCare(R) Infant Drops ... division of McNeil-PPC, Inc., announced today that the,company is voluntarily withdrawing ... directed, these medicines are generally,recognized as safe and effective. While most ...
... and Multimedia Healthcare Communication, PARIS, October 11 ... today two key acquisitions designed to reinforce its ... acquisitions,aim at strengthening Publicis Groupe,s leadership in both ... (Salerno), a highly innovative agency, specialized in,digital communications ...
... Has,a Story," a grassroots and integrated media project celebrating babies ... to survive and thrive --,has been launched by the March ... over the country tell,a special story about the baby they ... March of Dimes. "Families can also express their,hopes and dreams ...
... SACRAMENTO, Calif., Oct. 10 The governor ... (CSU) retirees to,participate in a self-funded comprehensive vision ... the Legislature and governor have recognized,the need to ... said,Barbara LaPlante, President of CSEA Retirees, Inc. "When ...
Cached Medicine News:Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 2Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 2Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 4Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 2Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 3Health News:Publicis Groupe Strengthens its Leadership in Digital and Integrated Healthcare Communications in Italy 4Health News:'Every Baby Has a Story' Campaign Tours the Nation for March of Dimes 2Health News:Governor Signs Bill Providing Vision Care Program for State University Retirees 2
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... aspiration holes and additional electrode tip ... precise dissection with decreased risk of ... ,Flexible design options allow the ... and multiple tip designs. Optimize specific ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: